We are live on !
Find out more
Johnson & Johnson Portfolio holdings
AUM
$762M
Turnover
0%
1-Year Est. Return
69.66%
This Fund
S&P 500
This Quarter Est. Return
+16.03%
1 Year Est. Return
+69.66%
3 Year Est. Return
+338.66%
5 Year Est. Return
+421.86%
10 Year Est. Return
–
AUM
$555M
AUM Growth
+$51.1M
(+10%)
Cap. Flow
-$9.33M
Cap. Flow % of AUM
Cap. Flow %
-1.68%
Top 10 Holdings %
Top 10 Hldgs %
98.34%
Holding
20
New
–
Increased
–
Reduced
2
Closed
3
Avg Time Held
3.2
years
Top 10 Avg Time Held
2.5
years
Top 20 Avg Time Held
3.2
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arrowhead Research
ARWR
|
+$8.54M |
| 2 |
CVRx
CVRX
|
+$717K |
| 3 |
Tessera Defense and Homeland Security Inc.
HLSQ
|
+$50.9K |
| 4 |
Senseonics Holdings Inc
SENS
|
+$23.8K |
| 5 |
Adicet Bio
ACET
|
+$11 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Protagonist Therapeutics
PTGX
$8.79B
| $214M | 38.54% |
2,449,183
| – | – |
2021 Q3
17 quarters
|
|
2
Nanobiotix
NBTX
$1.63B
| $130M | 23.43% |
5,623,816
| – | – |
2023 Q3
9 quarters
|
|
3
Rapport Therapeutics
RAPP
$1.55B
| $54.1M | 9.75% |
1,784,517
| – | – |
2024 Q2
6 quarters
|
|
4
MeiraGTx Holdings
MGTX
$911M
| $52.8M | 9.51% |
6,641,064
| – | – |
2021 Q3
17 quarters
|
|
|
5
CVRx
CVRX
$20.8M
| $28.6M | 5.15% |
4,024,861
-78,569
| -2% | -$717K |
2021 Q3
17 quarters
|
|
6
Contineum Therapeutics
CTNM
$404M
| $22.6M | 4.08% |
1,979,173
| – | – |
2024 Q2
6 quarters
|
|
7
Legend Biotech
LEGN
$4.72B
| $17.7M | 3.19% |
814,586
| – | – |
2021 Q3
17 quarters
|
|
8
Xencor
XNCR
$2.9B
| $11.5M | 2.06% |
748,062
| – | – |
2021 Q4
16 quarters
|
|
9
Procept Biorobotics
PRCT
$1.29B
| $11.3M | 2.03% |
357,939
| – | – |
2021 Q3
17 quarters
|
|
10
Fate Therapeutics
FATE
$236M
| $3.32M | 0.6% |
3,379,064
| – | – |
2021 Q3
17 quarters
|
|
11
Neumora Therapeutics
NMRA
$91.3M
| $3.31M | 0.6% |
1,849,445
| – | – |
2023 Q3
9 quarters
|
|
12
Rallybio
RLYB
$84.3M
| $2.49M | 0.45% |
454,545
| – | – |
2024 Q2
6 quarters
|
|
13
Lyell Immunopharma
LYEL
$379M
| $1.69M | 0.3% |
54,887
| – | – |
2024 Q4
4 quarters
|
|
14
Vor Biopharma
VOR
$1.23B
| $703K | 0.13% |
53,732
| – | – |
2021 Q3
17 quarters
|
|
15
Nano X Imaging
NNOX
$18.4M
| $445K | 0.08% |
158,852
| – | – |
2021 Q4
16 quarters
|
|
16
Standard BioTools
LAB
$274M
| $399K | 0.07% |
311,967
| – | – |
2024 Q1
7 quarters
|
|
|
17
Adicet Bio
ACET
$28M
| $192K | 0.03% |
22,779
-1
| -0% | -$11 |
2021 Q3
17 quarters
|
|
|
18
Arrowhead Research
ARWR
$6.96B
| – | – |
-247,598
| Closed | -$8.54M | – |
|
|
19
Tessera Defense and Homeland Security Inc.
HLSQ
$2.37M
| – | – |
-510
| Closed | -$50.9K | – |
|
|
20
Senseonics Holdings Inc
SENS
$518M
| – | – |
-2,731
| Closed | -$23.8K | – |
|
Similar funds
JC
Johnson & Johnson's Q4 2025 Portfolio in Review
As of Q4 2025, Johnson & Johnson held 20 positions worth $555M, up 10% from $504M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Johnson & Johnson's Q4 2025 filing shows 2 reduced and 3 closed positions. The largest sale was Arrowhead Research, an estimated $8.54M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Johnson & Johnson's biggest Q4 2025 reduction was CVRx, cutting an estimated $717K.
- Johnson & Johnson fully exited Arrowhead Research in Q4 2025, selling an estimated $8.54M.
- Johnson & Johnson's ten largest holdings make up 98% of its $555M portfolio in Q4 2025.
- Johnson & Johnson opened 0 new positions and closed 3 in Q4 2025.
- Johnson & Johnson's portfolio value rose 10% quarter-over-quarter to $555M.
Based on Johnson & Johnson's 13F filing for Q4 2025, filed 13 Feb 2026.